KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 7028 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
The efficacy and safety of a quadrivalent live attenuated influenza nasal vaccine in Japanese children: A phase 3, randomized, placebo-controlled study. PMID 38959995 · J Infect Chemother · 2025-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Intranasal Bencycloquidium Bromide in Nasal Symptoms of Common Cold: a Phase 3, Multicenter, Randomised, Double-blind, Placebo-controlled Trial. PMID 41476148 · QJM · 2025-Dec-31 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Intra-articular injection of umbilical cord-derived mesenchymal stem cells is safe and effective for moderate to severe knee osteoarthritis with synovitis: a double‑blinded and randomized controlled trial. PMID 41466394 · BMC Musculoskelet Disord · 2025-Dec-29 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A randomized, non-inferiority phase III clinical trial of immunogenicity and safety of 5-dose and 4-dose schedules of a freeze-dried human rabies vaccine (MRC-5 cells) in participants aged 10-60. PMID 41466188 · BMC Infect Dis · 2025-Dec-29 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201. PMID 41397917 · Oncologist · 2025-Dec-27 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 2 Panel · risk unclear
A randomized, controlled, multicenter phase III clinical trial of Huo Xiang Zheng Qi oral liquid for the prevention and control of nausea and vomiting caused by multiday cisplatin-based regimen. PMID 41466018 · Medicine (Baltimore) · 2025-Dec-26 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials. PMID 41448717 · BMJ Open · 2025-Dec-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Pharmacogenomic, pharmacokinetic, and safety analysis of CYP3A4/CYP3A5 polymorphisms of midostaurin in patients with acute myeloid leukemia. PMID 41432755 · Eur J Clin Pharmacol · 2025-Dec-23 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H L B
旧查询独有 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study. PMID 40924923 · Blood Adv · 2025-Dec-23 The record describes a long-term extension study (LTE1) analyzing a subgroup of patients who transitioned from ibrutinib to zanubrutinib from the parent ASPEN Phase III trial. While the parent trial was a Phase III randomized trial with a drug intervention, this specific report is not the original primary result of that trial. Furthermore, it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or HR; the outcomes are safety and disease response rates. The analysis is explicitly noted as nonrandomized/ad hoc for this subgroup.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial. PMID 41037766 · J Clin Oncol · 2025-Dec-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 3 Panel · risk unclear
Cost and cost-effectiveness of attractive targeted sugar baits (ATSB) in the context of a phase III cluster randomized control trial in Western Province, Zambia. PMID 41420162 · Malar J · 2025-Dec-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial. PMID 41413453 · BMC Infect Dis · 2025-Dec-18 The study is a randomized, placebo-controlled Phase III trial of a drug (HPV vaccine) with an oncology indication (prevention of cervical neoplasia). However, the primary efficacy endpoint is the proportion developing CIN2+, a categorical outcome, not a time-to-event endpoint like OS, PFS, or DFS. No Kaplan-Meier curves, hazard ratios, or other time-to-event analyses are reported in the abstract. Therefore, it does not meet the required time-to-event efficacy endpoint criterion.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial. PMID 41413016 · Signal Transduct Target Ther · 2025-Dec-18 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
Tolvaptan pharmacokinetics and pharmacodynamics in adolescents with autosomal dominant polycystic kidney disease. PMID 41407907 · Eur J Pediatr · 2025-Dec-18 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis. PMID 41406445 · N Engl J Med · 2025-Dec-18 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. PMID 41406444 · N Engl J Med · 2025-Dec-18 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. PMID 41124204 · N Engl J Med · 2025-Dec-18 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial. PMID 40991848 · Blood · 2025-Dec-18 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 3 Figure · 8 Panel · risk unclear
LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt/β-catenin vulnerability in T-ALL. PMID 40857670 · Blood · 2025-Dec-18 The abstract describes a biomarker/genetic analysis (LEF1 alterations) from Phase II/III T-ALL trial cohorts but does not report a primary or key secondary time-to-event efficacy endpoint (like OS, PFS, etc.) with Kaplan-Meier or HR results. It focuses on biological insights and treatment response associations, not definitive trial outcome data.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Interrater reliability in the assessment of oral mucositis among patients receiving high-dose chemotherapy: a multicenter comparison between specialized dentists and registered nurses. PMID 41408611 · BMC Cancer · 2025-Dec-17 The report is a methodological sub-study (interrater reliability) from a Phase III oncology trial, not the primary efficacy analysis. It lacks a time-to-event efficacy endpoint and does not report original trial results for a drug intervention.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Associations and predictive value of weight-adjusted waist index for cardiovascular outcomes in type 2 diabetes: evidence from the ACCORD study. PMID 41408264 · Nutr J · 2025-Dec-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term protection from naturally acquired immunity against hepatitis E virus reinfection. PMID 41407683 · Nat Commun · 2025-Dec-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Tegileridine for moderate-to-severe acute pain following abdominal surgery: A randomized, double-blind, phase 3 clinical trial. PMID 41365300 · Cell Rep Med · 2025-Dec-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome. PMID 41321238 · Circulation · 2025-Dec-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program: A Randomized Clinical Trial. PMID 41144242 · JAMA · 2025-Dec-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF: Insights From VICTOR. PMID 40892609 · J Am Coll Cardiol · 2025-Dec-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Exploratory Insights From the ODYSSEY-HCM Trial. PMID 40864019 · J Am Coll Cardiol · 2025-Dec-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial. PMID 41065506 · Clin Cancer Res · 2025-Dec-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma-An Exploratory Analysis of the STIC CTC Trial. PMID 41020765 · Clin Cancer Res · 2025-Dec-15 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
[Phase Ⅲ, multicenter, randomized, double-blinded, positive-controlled trial on the efficacy and safety of maribavir compared with valganciclovir in the treatment of post-transplant cytomegalovirus infection: Subgroup analysis of AURORA Trial in the Chinese population]. PMID 41486656 · Zhonghua Xue Ye Xue Za Zhi · 2025-Dec-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The patient reported intraocular lens questionnaire (PR-ILQ): content validity, psychometric performance, and use in a regulated clinical trial to evaluate safety and effectiveness outcomes. PMID 41385130 · J Patient Rep Outcomes · 2025-Dec-12 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of L-oxiracetam on cognitive function in patients with traumatic brain injury: a multicentre, randomised, double-blind, phase 3 clinical trial. PMID 41381424 · Signal Transduct Target Ther · 2025-Dec-12 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer. PMID 41124210 · N Engl J Med · 2025-Dec-11 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Efficacy and safety of daridorexant in Chinese patients with insomnia disorder: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial. PMID 40557879 · Sleep · 2025-Dec-11 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A composite biomarker score to predict modified Rodnan skin score in systemic sclerosis: insight from autologous stem cell transplantation international scleroderma trial. PMID 41372962 · Arthritis Res Ther · 2025-Dec-10 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009. PMID 41213101 · J Clin Oncol · 2025-Dec-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma. PMID 41187298 · J Clin Oncol · 2025-Dec-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma. PMID 40991874 · J Clin Oncol · 2025-Dec-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 4 Panel · risk unclear
Letrozole to prevent breast cancer in postmenopausal women with BRCA1/2 mutations (LIBER study). PMID 41240533 · Eur J Cancer · 2025-Dec-09 The study is an original Phase III randomized trial with a drug intervention (letrozole) and is oncology-focused in humans. However, the primary endpoint is incidence (5-year incidence of invasive BC), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) requiring Kaplan-Meier or HR for survival/disease progression. The hazard ratio provided is for incidence, not a standard time-to-event outcome.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial. PMID 41207182 · Eur J Cancer · 2025-Dec-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial. PMID 41175805 · Eur J Cancer · 2025-Dec-09 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trial. PMID 41138601 · Eur J Cancer · 2025-Dec-09 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Impact of tranexamic acid on postpartum hemorrhage in type 1 von Willebrand disease treated with recombinant VWF. PMID 40902088 · Blood Adv · 2025-Dec-09 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Twice-Daily Clopidogrel vs Ticagrelor to Reduce Short-Term Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention: The TADCLOT Trial. PMID 40892606 · J Am Coll Cardiol · 2025-Dec-09 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma. PMID 40829107 · Blood Adv · 2025-Dec-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial. PMID 41072417 · Cancer Cell · 2025-Dec-08 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy. PMID 41354932 · J Hematol Oncol · 2025-Dec-07 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H L S B
旧组与严格 v3 交集 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Influenza vaccines promote humoral and cellular immune responses: a randomized, double-blind, phase 3 trial. PMID 41354738 · Nat Commun · 2025-Dec-07 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Hydroxychloroquine does not affect endotheliopathy or coagulopathy biomarkers in COVID-19: longitudinal results from the DisCoVeRy randomized trial. PMID 41353681 · Angiogenesis · 2025-Dec-07 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H L
旧查询独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Expanding insights from the VISTA phase III trial: longitudinal comparative assessment of ellipsoid zone integrity and volumetric fluid dynamics. PMID 41350590 · Sci Rep · 2025-Dec-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -